We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+4.87%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$1.7B
AUM Growth
-$254M
Cap. Flow
-$154M
Cap. Flow %
-9.05%
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
7

Top Buys

Rank Stock Value
1
MMED
MiniMed Group Inc
MMED
+$17.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15M
3
BSX icon
Boston Scientific
BSX
+$9.3M
4
HTFL
Heartflow Inc
HTFL
+$8M
5
PTCT icon
PTC Therapeutics
PTCT
+$7.08M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$61.1M
2
CDTX
Cidara Therapeutics
CDTX
+$45.3M
3
FOLD
Amicus Therapeutics
FOLD
+$27.4M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24M
5
TVTX icon
Travere Therapeutics
TVTX
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$118M 6.93%
1,209,465
-125,805
-9% -$12.7M
LLY icon
2
Eli Lilly
LLY
$1.05T
$90.8M 5.35%
98,700
-6,700
-6% -$6.79M
MDGL icon
3
Madrigal Pharmaceuticals
MDGL
$12.3B
$89.5M 5.28%
170,999
+31,381
+22% +$15M
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$5.94B
$74.9M 4.42%
811,294
+49,000
+6% +$4.61M
ARGX icon
5
argenx
ARGX
$64B
$71.9M 4.24%
98,500
-4,750
-5% -$3.72M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.38B
$60M 3.54%
689,748
-5,262
-0.8% -$512K
INSM icon
7
Insmed
INSM
$25.9B
$51.4M 3.03%
314,300
-4,950
-2% -$761K
ASND icon
8
Ascendis Pharma A/S
ASND
$16.3B
$44.4M 2.62%
194,000
-9,500
-5% -$2.13M
XENE icon
9
Xenon Pharmaceuticals
XENE
$5.81B
$44.4M 2.62%
763,020
-24,768
-3% -$1.14M
TVTX icon
10
Travere Therapeutics
TVTX
$6.19B
$43.9M 2.59%
1,477,954
-732,368
-33% -$21.9M
KYMR icon
11
Kymera Therapeutics
KYMR
$9.82B
$41.4M 2.44%
496,871
– –
PEN icon
12
Penumbra
PEN
$12.7B
$39.6M 2.33%
120,500
– –
ISRG icon
13
Intuitive Surgical
ISRG
$132B
$37.8M 2.23%
82,000
– –
SRRK icon
14
Scholar Rock
SRRK
$7.04B
$36.4M 2.14%
739,816
+6,339
+0.9% +$284K
ELVN icon
15
Enliven Therapeutics
ELVN
$4.24B
$32.4M 1.91%
826,500
+28,095
+4% +$778K
BSX icon
16
Boston Scientific
BSX
$67.9B
$32.3M 1.91%
515,300
+116,250
+29% +$9.3M
IRTC icon
17
iRhythm Holdings
IRTC
$3.96B
$30.9M 1.82%
261,750
+26,750
+11% +$3.86M
GPCR icon
18
Structure Therapeutics
GPCR
$3.38B
$30.9M 1.82%
640,217
-108,019
-14% -$7.39M
AGIO icon
19
Agios Pharmaceuticals
AGIO
$1.99B
$27M 1.59%
799,163
– –
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.52B
$25.5M 1.5%
1,218,773
-48,468
-4% -$1.09M
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$31.7B
$24.5M 1.44%
74,000
+2,750
+4% +$936K
COGT icon
22
Cogent Biosciences
COGT
$6.02B
$24M 1.42%
624,155
-224,875
-26% -$8.3M
THC icon
23
Tenet Healthcare
THC
$21.5B
$23.6M 1.39%
125,000
– –
DXCM icon
24
DexCom
DXCM
$34.3B
$22.3M 1.32%
355,600
+8,300
+2% +$578K
CLDX icon
25
Celldex Therapeutics
CLDX
$3.07B
$20.6M 1.22%
650,270
-42,268
-6% -$1.15M
1
2 3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rock Springs Capital Management held 107 positions worth $1.7B, down 13% from $1.95B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Rock Springs Capital Management withdrew a net $154M in Q1 2026, closing 7 positions and reducing 24 holdings. Its most notable exit was Exact Sciences, an estimated $61.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Rock Springs Capital Management opened a new position in MiniMed Group Inc worth $15.7M.

  • Rock Springs Capital Management's largest Q1 2026 buy was MiniMed Group Inc: 1,055,000 shares worth $15.7M.
  • Rock Springs Capital Management added most to Madrigal Pharmaceuticals in Q1 2026, an estimated $15M increase.
  • Rock Springs Capital Management's biggest Q1 2026 reduction was Amicus Therapeutics, cutting an estimated $27.4M.
  • Rock Springs Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $61.1M.
  • Rock Springs Capital Management's ten largest holdings make up 41% of its $1.7B portfolio in Q1 2026.
  • Rock Springs Capital Management opened 9 new positions and closed 7 in Q1 2026.
  • Rock Springs Capital Management's portfolio value fell 13% quarter-over-quarter to $1.7B.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.